17 Paul Tudor Jones II ADT Trades
The first ADT trade was made in Q3 2018. Since then Paul Tudor Jones II bought shares seven more times and sold shares on nine occasions. The investor sold all their shares in Q3 2023 and doesn't own any shares in ADT anymore.
Avg closing price
Price range
Sold -273 Thousand shares
Q3 2023
Avg closing price
$6.23
Price range
$5.82
-
$6.71
New holding (+273 Thousand shares)
Q2 2023
Avg closing price
$6.26
Price range
$5.13
-
$7.16
Sold -54.7 Thousand shares
Q1 2023
Avg closing price
$8.15
Price range
$6.94
-
$9.79
Increased shares by 157.9% (+33.5 Thousand shares)
Q4 2022
Avg closing price
$8.89
Price range
$7.78
-
$9.86
New holding (+21.2 Thousand shares)
Q3 2022
Avg closing price
$7.54
Price range
$6.29
-
$8.66
Sold -176 Thousand shares
Q2 2021
Avg closing price
$10.05
Price range
$8.46
-
$11.63
New holding (+176 Thousand shares)
Q1 2021
Avg closing price
$8.66
Price range
$6.87
-
$10.25
Sold -887 Thousand shares
Q4 2020
Avg closing price
$7.85
Price range
$6.59
-
$8.69
New holding (+887 Thousand shares)
Q3 2020
Avg closing price
$9.73
Price range
$7.40
-
$13.48
Sold -131 Thousand shares
Q2 2020
Avg closing price
$6.47
Price range
$4.09
-
$8.53
Sold 16.2% shares (-25.2 Thousand shares)
Q1 2020
Avg closing price
$6.05
Price range
$3.72
-
$7.57
Sold 58.9% shares (-224 Thousand shares)
Q4 2019
Avg closing price
$7.90
Price range
$6.19
-
$9.57
Sold 42.9% shares (-286 Thousand shares)
Q3 2019
Avg closing price
$5.67
Price range
$4.35
-
$6.56
Increased shares by 379.4% (+527 Thousand shares)
Q2 2019
Avg closing price
$6.37
Price range
$5.85
-
$6.99
Increased shares by 84.8% (+63.7 Thousand shares)
Q1 2019
Avg closing price
$7.22
Price range
$6.16
-
$8.19
Sold 67.0% shares (-153 Thousand shares)
Q4 2018
Avg closing price
$7.53
Price range
$6.01
-
$9.20
New holding (+228 Thousand shares)
Q3 2018
Avg closing price
$8.91
Price range
$8.05
-
$9.48
News about ADT Inc and Paul Tudor Jones II
Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)
WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARANOTE trial, investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with m...
ADT Appoints William M. Lewis Jr. to the Company''s Board of Directors
BOCA RATON, Fla., June 16, 2022 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT ), the most trusted brand in smart home and small business security, today announced ...